A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01263223
First received: December 16, 2010
Last updated: April 1, 2011
Last verified: April 2011
  Purpose

The purpose of this study is to determine the effect of LY2216684 on heart rate and blood pressure in research participants with MDD who are being treated with an SSRI (selective serotonin reuptake inhibitors). Information about any side effects that may occur will also be collected. The duration of participation in this study is approximately 24 days not including the screening visit. This study requires 1 clinic confinement of 17 days/16 nights and 1 Follow-up Outpatient Visit. A screening visit is required within 30 days prior to the start of the study. In both periods 1 and 2, the study involves 4 single daily doses of 18 mg LY2216684 or placebo taken as 2 tablets by mouth. In period 3, the study involves four single daily doses of 36 mg LY2216684 or placebo taken as 4 tablets by mouth.


Condition Intervention Phase
Major Depressive Disorder
Drug: LY2216684
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • The maximum, minimum and average changes in ambulatory heart rate from baseline, will be used for primary analysis. [ Time Frame: Over the 24 hours interval on days 1 and 4 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Ambulatory systolic and diastolic blood pressure (18mg) [ Time Frame: Over the 24 hours interval on Days 1 and 4 ] [ Designated as safety issue: Yes ]
  • Ambulatory heart rate (36mg) [ Time Frame: Over the 24 hours interval on Days 1 and 4 ] [ Designated as safety issue: Yes ]
  • Ambulatory systolic and diastolic blood pressure (36mg) [ Time Frame: Over the 24 hours interval on Days 1 and 4 ] [ Designated as safety issue: Yes ]
  • Ambulatory heart rate (18 to 36mg) [ Time Frame: Over the 24 hours interval on Days 1 and 4 ] [ Designated as safety issue: Yes ]
  • Ambulatory systolic and diastolic blood pressure (18 to 36mg) [ Time Frame: Over the 24 hour interval on Days 1 and 4 ] [ Designated as safety issue: Yes ]

Enrollment: 0
Study Start Date: December 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LY2216684, placebo, LY or placebo

Period 1: 18 mg LY2216684 administered orally once daily on days 1-4

Period 2: placebo administered orally once daily on days 1-4

Period 3: 36 mg LY2216684 or placebo administered orally daily on days 1-4

Drug: LY2216684
Administered orally
Drug: Placebo
Administered orally
Experimental: Placebo, LY2216684, placebo or LY

Period 1: placebo administered orally once daily on days 1-4

Period 2: 18 mg LY2216684 administered orally once daily on days 1-4

Period 3: 36 mg LY2216684 or placebo administered orally daily on days 1-4

Drug: LY2216684
Administered orally
Drug: Placebo
Administered orally

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Are patients that have been diagnosed with MDD and are on a stable dose of an selective serotonin reuptake inhibitor (SSRI) for at least 4 weeks prior to enrollment, as determined by medical history and physical examination.
  • Male patients: Agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug.
  • Female patients - Are women of child-bearing potential who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control for 6 weeks prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or Women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause for at least 1 year without menses or 6 months without menses and a follicle stimulating hormone (FSH) >40 mIU/mL.
  • Have a body mass index (BMI) of up to 32.0 kg/m2.
  • Have normal BP and pulse rate (systolic BP <140, diastolic BP <90; supine position and standing) as determined by the investigator.
  • Patients that have a diagnosis of hypertension but are well controlled on a stable dose (at least 4 weeks of diuretic, angiotensin converting enzyme [ACE]-inhibitor, or angiotensin 2 receptor inhibitor) are acceptable for inclusion in this study. Allowance of a specific anti-hypertensive is per the investigator's discretion.
  • Have screening clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
  • Have venous access sufficient to allow blood sampling as per the protocol.
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  • Have given written informed consent approved by Lilly and the institutional review board (IRB) governing the site.

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device other than the study drug used in this study, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have known allergies to any compound related to LY2216684.
  • Are persons who have previously completed or withdrawn from this study or any other study investigating LY2216684.
  • Have a clinically significant abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Have a significant history of or presence of cardiovascular (including dysrhythmias), respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders, or any condition capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Have unequal BP (> 20 mm Hg) in the left arm versus right arm (as measured with a BP cuff) or have absent or unequal radial pulses in either arm.
  • Have a history of seizure disorders.
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  • Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.
  • Show evidence of hepatitis C and/or positive hepatitis C antibody.
  • Show evidence of hepatitis B and/or positive hepatitis B surface antigen.
  • Are women with a positive pregnancy test or women who are lactating.
  • Use of over-the-counter or prescription medication (other than stable doses of SSRI as noted above) with a narrow therapeutic index (including, but not limited to warfarin or clopidogrel) or those that are known to have an effect on heart rate (e.g., beta-blockers) within 14 days prior to dosing.
  • Use of any drugs or substances that are known to be a strong inducer or inhibitor of CYP2D6 or CYP3A4 within 30 days prior to check-in (study entry) and during the conduct of the study.
  • Have donated blood of more than 500 mL within 4 weeks prior to screening.
  • Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption 48 hours prior to check-in (study entry)until the completion of the study (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any patients unwilling to adhere to study caffeine restrictions.
  • Patients must adhere to the smoking restrictions of the Clinical Research Unit (CRU) while a resident of the CRU.
  • Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment or are unwilling to avoid during the study.
  • Have a documented or suspected history of glaucoma.
  • Patients determined to be unsuitable by the investigator for any reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01263223

Locations
United States, Missouri
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
St Louis, Missouri, United States, 63118
United States, Texas
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Austin, Texas, United States, 78731
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Chief Medical Officer, Eli Lilly
ClinicalTrials.gov Identifier: NCT01263223     History of Changes
Other Study ID Numbers: 12607, H9P-EW-LNCP
Study First Received: December 16, 2010
Last Updated: April 1, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Serotonin
Serotonin Uptake Inhibitors
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on July 22, 2014